Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study. - Douma, Li-Anne H; van der Noort, Vincent; Lalezari, Ferry; de Vries, Jeltje F; Monkhorst, Kim; Smesseim, Illaa; Baas, Paul; Schilder, Bodien; Vermeulen, Marrit; Burgers, Jacobus A; de Gooijer, Cornedine J (Lancet Oncology, 2025)